My Research Publications

 

 

 

 

1.     Smith D, Helgason H, Sulem P, Lim AC, Sveinbjornsson G, Hasegawa H, Brown M, Ketchem R, Gavala M, Garrett L, Jonasdottir A, Jonasdottir A, Sigurdsson A,  Magnusson OT, Eyjolfsson GI, Olafsson I, Onundarson TP, Sigurdardottir O, Gislason D, Gislason T, Ludviksson BR, Ludviksottir D,  Boezen MH, Heinzmann A, Krueger M, Porsbjerg C, Ahluwalia TS, Wage J, Backer V, Deichmann KA, Koppelman GA, Bønnelykke K, Bisgaard H, Masson G,  Thorsteinsdottir U, Gudbjartsson DF, Björnsdottir US,  Johnston JA, Jonsdottir I and Stefansson K. A rare IL33 Loss-of-function mutation reduces blood eosinophil counts and protects from asthma. PLOS Genetics. 2017. March 8. http://dx.doi.org/10.1371/journal.pgen.1006659

 

2.     Tyler M, Russell CB, Smith DE, Padro CJ, Citardi MJ, Fakhri S, Assassi S, MD and Luong A. Large scale gene expression profiling reveals distinct type 2 inflammatory patterns in chronic rhinosinusitis subtypes. J Allergy Clin Immunol. 2017. Mar;139(3):1061-1064.

 

3.     Mathews JA, Krishnamoorthy N, Kasahara DI, Cho Y, Wurmbrand AP, Ribeiro L, Smith DE, Umetsu D, Levy BD, and Shore SA. IL-33 drives augmented responses to ozone in obese mice. Environmental Health Perspectives. 2017. Feb;125(2):246-253.

 

4.     Vannella KM, Ramalingam TR, Borthwick LA, Barron L, Hart KM, Thompson RW, Kindrachuk KN, Cheever AW, White S, Budelsky AL, Comeau MR, Smith DE, and Wynn TA.  Combinatorial Targeting of TSLP, IL-25, and IL-33 in Type 2 Cytokine-driven Inflammation and Fibrosis. Science Translational Medicine. 2016 May; 8(337).

 

5.     De Salvo C, Wang XM, Pastorelli L, Mattioli B, Omenetti S, Buela KA, Chowdhry S, Garg RR, Goodman WA, Rodriguez-Palacios A, Smith DE, Abbott DW, Cominelli F, Bamias G, Xin W, Lee JJ, Vecchi M and Pizarro TT. IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental Ileitis. Am J Pathol. 2016 Apr;186(4):885-98.

 

6.     Heaney LG, Djukanovic R, Woodcock A, Walker S, Matthews JG, Pavord ID, Bradding P, Niven R, Brightling CE, Chaudhuri R, Arron JR, Choy DF, Cowan D, Mansur A, Menzies-Gow A, Adcock I, Chung KF, Corrigan C, Coyle P, Harrison T, Johnston S, Howarth P, Lordan J, Sabroe I, Bigler J, Smith D, Cattley M, May R, Pierre L, Stevenson C, Crater G, Keane F, Costello RW, Hudson V, Supple D, Hardman T. Research in Progress – Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax. 2016 Feb;71(2):187-9.

 

7.     Martin P, Palmer G, Rodriguez E, Woldt E, Mean I, James RW, Smith DE, Kwak BR and Gabay C. Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signaling. Immun Inflamm Dis. 2015 Sep;3(3):239-46.

 

8.     Chandra S, Zhao M, Budelsky A, Pulido ADM, Day J, Fu Z, Siegel L, Smith D and Kronenberg M. A new mouse strain for the analysis of invariant NKT cell function. Nature Immunology. 2015 Aug;16(8):799-800.

 

9.     Hirota JA, Gold MJ, Hiebert PR, Parkinson LG, Wee T, Smith D, Hansbro PM, Carlsten C, VanEeden S, Sin DD, McNagny KM and Knight DA. The NLRP3 inflammasome/IL-1RI axis mediates innate immune but not adaptive immune responses following PM10 exposure AJRCMB. 2015 Jan;52 (1):96-105.

 

10.  Lai Y, Altemeier WA, Vandree J, Piliponsky AM, Johnson B, Appel CL, Frevert CW, Hyde DM, Ziegler SF, Smith DE, Henderson WR Jr, Gelb MH and Hallstrand TS. Increased density of intraepithelial mast cells in patients with exercise-induced bronchoconstriction regulated through epithelially derived thymic stromal lymphopoietin and IL-33. J Allergy Clin Immunol. 2014 May;133 (5):1448-55.

 

11.  Martin P, Talabot-Ayer D, Seemayer CA, Vigne S, Lamacchia C, Rodriguez E, Finckh A, Smith DE, Gabay C and Palmer G. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res Ther. 2013 Jan;15(1):R13.

 

12.  Hung LY, Lewkowich IP, Dawson LA, Downey J, Yang Y, Smith DE and Herbert DR. IL-33 drives biphasic IL-13 production for noncanonical Type 2 immunity against hookworms. Proc Natl Acad Sci U S A. 2013 Jan;110(1):282-7.

 

13.  Beamer CA, Girtsman TA, Seaver BP, Finsaas KJ, Migliaccio CT, Perry VK, Rottman JB, Smith DE and Holian A. IL-33 mediates multi-walled carbon nanotube (MWCNT)-induced airway hyper-reactivity via the mobilization of innate helper cells in the lung. Nanotoxicology. 2013 Sep;7(6):1070-81.

 

14.  Lipsky BP, Toy DY, Swart DA, Smithgall MD and Smith D. Deletion of the ST2 proximal promoter disrupts fibroblast-specific expression but does not reduce the amount of soluble ST2 in circulation. Eur J Immunol. 2012 Jul;42(7):1863-9.

 

15.  Wills-Karp M, Rani R, Dienger K, Lewkowich I, Fox JG, Perkins C, Lewis L, Finkelman FD, Smith DE, Bryce PJ, Kurt-Jones EA, Wang TC, Sivaprasad U, Hershey GK and Herbert DR. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J Exp Med. 2012 Mar;209(3):607-22.

 

16.  Ngoi SM, St Rose MC, Menoret AM, Smith DE, Tovey MG, Adler AJ and Vella AT. Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc Natl Acad Sci U S A. 2012 June;109(26):10486-91.

 

17.  Kim HY, Chang YJ, Subramanian S, Lee HH, Albacker LA, Matangkasombut P, Savage PB, McKenzie ANJ, Smith DE, Rottman JB, DeKruyff RH and Umetsu DT. Innate lymphoid cells responding to IL-33 mediate 1 airway-hyperreactivity independent of adaptive immunity. J Allergy Clin Immunol. 2012 Jan;129(1):216-227.

 

18.  Taishi P, Davis CJ, Bayomy O, Zielinski MR, Liao F, Clinton JM, Smith DE and Krueger JM. Brain-specific interleukin-1 receptor accessory protein in sleep regulation. J Appl Physiol. 2012 Mar;112(6):1015-22.

 

19.  Huang Y, Smith DE, Ibáñez-Sandoval O, Sims JE, and Friedman WJ. Neuron-Specific Effects of Interleukin-1ß are Mediated by a Novel Isoform of the IL-1 Receptor Accessory Protein. J Neuroscience. 2011 Dec;31(49):18048-59.

 

20.  Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, Dekruyff RH and Umetsu DT.  Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011 May 29;12(7):631-8.

 

21.  Dirk E. Smith. The biological paths of IL-1 family members IL-18 and IL-33. J. Leuk. Biol. 2011 Mar;89(3):383-92. Invited Review.

 

22.  Sims JE and Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010 Feb;10(2):89-102. Invited Review.

 

23.  Smith, DE. IL-33: A Tissue Derived Cytokine Pathway Involved in Allergic Inflammation and Asthma. Clin Exp Allergy. 2010 Feb;40(2):200-8. Invited Review.

 

24.  Hirota JA, Budelsky A, Smith D, Lipsky B, Ellis R, Xiang YY, Lu WY and Inman MD. The role of interleukin-4Ralpha in the induction of glutamic acid decarboxylase in airway epithelium following acute house dust mite exposure. Clin Exp Allergy. 2010 May;40(5):820-30.

 

25.  Smith DE, Lipsky BP, Russell C, Ketchem RR, Kirchner J, Hensley K, Boissonneault V, Plante MM, Rivest S, Huang Y, Friedman WJ and Sims JE. A Novel CNS-Restricted Isoform of the IL-1R Accessory Protein Modulates Neuronal Responses to IL-1. Immunity. 2009 Jun;30(6):817-31.

 

26.  Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, Finckh A, Smith DE and Gabay C. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 2009 Mar;60(3):738-49.

 

27.  Allakhverdi Z, Comeau MR, Smith DE, Toy D, Endam LM, Desrosiers M, Liu YJ, Howie KJ, Denburg JA, Gauvreau GM and Delespesse G. CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol. 2009 Feb;123(2):472-8.

 

28.  Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R and Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008 Aug;20(8):1019-30. (Featured Article of the Month, cited over 300 times).

 

29.  Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, Gabay C and Smith DE. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine. 2008 Jun 42(3):358-64.

 

30.  Allakhverdi Z, Smith DE, Comeau MR and Delespesse G. Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol. 2007 Aug;179(4):2051-4.

 

31.  Smith DE, Hanna R, Della Friend, Moore H, Chen H, Farese AM, MacVittie TJ, Virca GD, Sims JE. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 2003 Jan;18(1):87-96.

 

32.  John E. Sims and Dirk E. Smith, Regulation of Interleukin-1 activity is enhanced by cooperation between the interleukin-1 receptor type II and interleukin-1 receptor accessory protein. Eur. Cytokine Netw. 2003 June;15(2):77-81. Review.

 

33.  Smith DE, Ketchem RR, Moore H, Anderson Z, Renshaw BR, Friend DJ and Sims JE. A Single Amino Acid Difference between Human and Monkey Interleukin (IL)-1beta Dictates Effective Binding to Soluble Type II IL-1 Receptor. J Biol Chem. 2002 Dec;277(49):47619-25.

 

34.  Taylor SL, Renshaw BR, Garka KE, Smith DE and Sims JE. Genomic organization of the interleukin-1 locus. Genomics. 2002 May;79(5):726-33.

 

35.  Sims JE, Pan Y, Smith DE, Nicklin MJ, Barton JL, Bazan JF, Kastelein RA, Busfield SJ, Ford JE, Lin H, Mulero JJ, Kumar S, Pan J and Young PR. A new nomenclature for IL-1-family genes. Trends Immunol. 2001 Oct;22(10):536-7.

 

36.  Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA and O'Neill LA. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature. 2001 Sep;413(6851):78-83.

 

37.  Born TL, Smith DE, Garka KE, Renshaw BR, Bertles JS and Sims JE. Identification and characterization of two members of a novel class of the interleukin-1 receptor (IL-1R) family. Delineation Of a new class of IL-1R-related proteins based on signaling. J Biol Chem. 2000 Dec;275(52):41528-.

 

38.  Smith DE, Renshaw BR, Ketchem RR, Kubin M, Garka KE and Sims JE. Four new members expand the interleukin-1 superfamily. J Biol Chem. 2000 Jan;275(2):1169-75.

 

39.  McCoy C, Smith DE and Cornwell MM. 12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1. Mol Cell Biol. 1995 Nov;15(11):6100-8.

 

40.  Miltenberger RJ, Farnham PJ, Smith DE, Stommel JM and Cornwell MM. v-Raf activates transcription of growth-responsive promoters via GC-rich sequences that bind the transcription factor Sp1. Cell Growth Differ. 1995 May;6(5):549-56.

 

41.  Cornwell MM and Smith DE. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem. 1993 Sep;268(26):19505-11.

 

42.  Cornwell MM and Smith DE. A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase. J Biol Chem. 1993 Jul;268(21):15347-50.

 

43.  Smith DE and Klein AS. Phylogenetic inferences on the relationship of North American and European Picea species based on nuclear ribosomal 18S sequences and the internal transcribed spacer 1 region. Mol Phylogenet Evol. 1994 Mar;3(1):17-26.

 

44.  Bobola MS, Smith DE and Klein AS.  Five major nuclear ribosomal repeats represent a large and variable fraction of the genomic DNA of Picea rubens and P. mariana. Mol Biol Evol. 1992 Jan;9(1):125-37.